DNAM-1/CD226 Antibody

CD226 is a 65kD type I transmembrane glycoprotein, known as DNAM-1 (DNAX accessory molecule-1), PTA1(platelet and T cell activation antigen 1), or TLiSA1 (T lineage-specific activation antigen 1 antigen). It belongs to immunoglobulin superfamily containing 2 Ig-like domains, is expressed on majority of T lymphocytes, NK cells, monocytes, platelets, and a subset of B cells, activated endothelial cells. DNAM-1 is also expressed on CD8+ (but not CD8-) dendritic cells in mouse model. CD226 is an adhesion molecule involved in CTL and NK cell-mediated cytotoxicity. It has been identified that CD155 (poliovirus receptor, PVR) and CD112 (nectin-2, PRR-2) are CD226 ligands. DX11 antibody is able to inhibit CTL and NK cell-mediated cytotoxicity, and to block T cell cytokine production.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: IF/IHC.

Showing Publication 1 - 1 of 1.

Publication using NBP1-85001	Applications	Species
Lucca LE, Lerner BA, Park C et al. Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS Neurol Neuroimmunol Neuroinflamm 2020-05-04 [PMID: 32269065] (IF/IHC, Human)	IF/IHC	Human

Array NBP1-85001

• DNAM-1/CD226 Antibodies
• DNAM-1/CD226 Lysate
• DNAM-1/CD226 Proteins
• DNAM-1/CD226 ELISA
• DNAM-1/CD226 Proteins and Enzymes